An Update on the Management of Acquired Hemophilia A

Acquired hemophilia A (AHA) is a rare bleeding disorder caused by autoantibodies against human factor VIII. About half of cases are idiopathic, and the prevalence of AHA is likely an underestimate because it often goes unrecognized or is mistaken for congenital or other acquired bleeding disorders. Mortality rates may be as high as 22%, especially early in the disease, so prompt recognition and treatment are necessary to keep morbidity and mortality low. Hemostatic treatment with bleeding suppression and immunosuppression are required in up to 70% of patients, as well as treatment of any underlying pathology. Recent reviews of the management of AHA have identified a number of clinical practice gaps and need for practitioner education in the timely recognition and evidence-based therapy of AHA. In this symposium, expert faculty will discuss at-risk patient groups, differential diagnosis, relevant laboratory findings, appropriate treatment, safety concerns, and the need for long-term monitoring in AHA to prevent relapse of bleeding complications.